Bridging the gap between preclinical and clinical studies using pharmacokinetic–pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor

H Wong, L Vernillet, A Peterson, JA Ware, L Lee… - Clinical Cancer …, 2012 - AACR
Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal–regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic–pharmacodynamic …
被引用次数：96 相关文章

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.

H Wong, L Vernillet, A Peterson, JA Ware… - … Cancer Research: an …, 2012 - europepmc.org
Purpose GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal-regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic-pharmacodynamic …
[PDF] archive.org

[PDF][PDF] Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

H Wong, L Vernillet, A Peterson, JA Ware… - Clin Cancer …, 2012 - scholar.archive.org
Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal–regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic–pharmacodynamic …

[引用][C] Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

H WONG, L VERNILLET, KP HOEFLICH… - Clinical cancer …, 2012 - pascal-francis.inist.fr
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic
Modeling: An Analysis of GDC-0973, a MEK Inhibitor CNRS Inist Pascal-Francis CNRS …
[PDF] academia.edu

[PDF][PDF] Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

H Wong, L Vernillet, A Peterson, JA Ware, L Lee… - Clin Cancer …, 2012 - academia.edu
Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal–regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic–pharmacodynamic …

Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor

H Wong, L Vernillet, A Peterson… - … : an official journal …, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal-regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic-pharmacodynamic …

[引用][C] Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

H Wong, L Vernillet, A Peterson, JA Ware, L Lee… - Clinical Cancer …, 2012 - cir.nii.ac.jp
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic
Modeling: An Analysis of GDC-0973, a MEK Inhibitor | CiNii Research CiNii 国立情報学 …
[PDF] researchgate.net

[PDF][PDF] Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

H Wong, L Vernillet, A Peterson, JA Ware, L Lee… - Clin Cancer …, 2012 - researchgate.net
Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal–regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic–pharmacodynamic …
[PDF] academia.edu

[PDF][PDF] Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

H Wong, L Vernillet, A Peterson, JA Ware, L Lee… - Clin Cancer …, 2012 - academia.edu
Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal–regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic–pharmacodynamic …